UNSPSC 42143103: Contraceptive devices for female users

In this classification, this commodity indicates a product of various forms used to prevent pregnancy. Most nations, for tariff and trade purposes, schedule these products under HS 901811.

UNSPSC 42143103 Contraceptive devices for female users is a Commodity code that frames a narrow product category, yet recent state and local solicitations under this code show minimal direct activity specifically targeting contraceptive devices. Instead, the opportunities posted reflect broader pharmaceutical and OTC product procurement that subsumes contraceptive products within larger multi-source drug catalogs. State and local issuing bodies—primarily health and human services departments, state pharmacy benefit programs, and cooperative purchasing alliances—use codes in this family to manage contraceptive supply through general pharmaceutical contracting rather than dedicated device procurement. The actual scope of work involves manufacturers and vendors supplying contraceptive devices alongside generic pharmaceuticals, biosimilars, and OTC products to state employee health plans, Medicaid programs, and participating local health systems, with manufacturers responsible for providing product specifications, maintaining regulatory compliance, and supporting direct-to-pharmacy or direct-to-wholesaler distribution channels.

Recent opportunities show activity concentrated in Minnesota and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; awarded vendors must be available through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) with contracts effective July 1, 2026. The Texas Health and Human Services Commission issued Request for Information RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative that would establish direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Neither the MMCAP RFP nor the Texas RFI specifies contract values or set-asides. The code shows limited recent solicitation activity specifically targeting contraceptive devices as a distinct procurement focus; opportunities in this category appear episodic and embedded within broader pharmaceutical buying initiatives rather than standalone device contracts.